Galmed Pharmaceuticals Ltd. (GLMD) Form 6-K — Aug 19, 2026
Galmed Pharmaceuticals announced successful first-in-human proof-of-concept results for a novel intraoperative tissue assessment technology developed by its wholly owned subsidiary Colospan. The platform is Colospan's second technology, expanding the pipeline beyond its lead CG-100 intraluminal bypass device. The prospective, single-arm feasibility study enrolled 32 colorectal cancer patients at three leading Israeli medical centers and achieved successful quantitative colon tissue measurements in all 32 patients, with no measurement failures or procedure-related technical issues.
Key figures
- Study sites
- 3
- Study design
- prospective, single-arm feasibility study
- Patients enrolled
- 32
- Measurement failures
- 0
- Successful measurements
- 32 of 32
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.